SBIR TOPIC 425 PHASE I: POSTURE ANALYSIS THROUGH MACHINE LEARNING (PATHML)

SBIR 主题 425 第一阶段：通过机器学习进行姿势分析 (PATHML)

• 批准号: 10931985
• 负责人: ARFAAN RAMPERSAUD
• 金额: $ 35.5万
• 依托单位: COLUMBUS NANOWORKS, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-27 至 2024-02-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10931985
• 关键词: Biological Markers; Breast Cancer Patient; Cancer Patient; Comparative Study; Complement; Consensus; Data; Detection; Development; Diagnostic; Diagnostic tests; Diamond; Life; Machine Learning; Magnetic nanoparticles; Magnetometries; Methods; MicroRNAs; Monitor; Nitrogen; Optics; Paraffin Embedding; Pattern; Performance; Phase; Posture; RNA Sequences; Reporting; Research; Reverse Transcriptase Polymerase Chain Reaction; Small Business Innovation Research Grant; Specific qualifier value; Technology; Time; Tissue Embedding; Untranslated RNA; advanced breast cancer; aggressive breast cancer; cancer biomarkers; detection limit; inflammatory breast cancer; magnetic field; molecular marker; nanodiamond; point of care; predictive signature; quantum

Inflammatory breast cancer, (IBC), is a rare and highly aggressive subtype of advanced breast cancer. Small, non-coding RNAs, microRNAs or miRs, are molecular biomarkers for IBC although there is no consensus miR pattern for IBC. RT-PCR, the gold standard for miR profiling, has identified a 5-miR signature predictive of IBC aggressiveness. Other technologies are still needed that can confirm these results and complement (or even supplant) RT-PCR methods. This project will use Diamond Magnetometry (DM) as an advanced quantum-based, all-optical technology for rapid, ultrasensitive sensing of molecules. DM uses fluorescent, nitrogen-vacancy center nanodiamonds (FNDs) to sense/detect very weak magnetic fields. In Objective 1, we will exploit FNDs and magnetic nanoparticles to detect three of the five miR biomarkers of IBC using a microchannel format. In Objective 2, we will determine performance parameters for DM and demonstrate the technology using FFPE from normal and breast cancer patients. This will include a comparison of DM to RT-PCR. Sensing miR targets with DM will be transformative and radically alter how we use and monitor cancer biomarkers. Development of this quantum-based technology will reduce diagnostic testing time from days to minutes, and make real-time, point of care possible, saving money, time, and lives.

炎症性乳腺癌（IBC）是一种罕见的、高度侵袭性的晚期乳腺癌亚型。小的非编码rna、microrna或miRs是IBC的分子生物标志物，尽管IBC的miR模式尚未达成共识。RT-PCR是miR分析的金标准，已经确定了IBC侵袭性的5-miR特征预测。仍然需要其他技术来证实这些结果，并补充（甚至取代）RT-PCR方法。该项目将使用金刚石磁强计（DM）作为一种先进的基于量子的全光技术，用于快速、超灵敏地检测分子。DM使用荧光、氮空位中心纳米金刚石（FNDs）来感知/探测非常弱的磁场。在目标1中，我们将利用fnd和磁性纳米颗粒使用微通道格式检测IBC的五种miR生物标志物中的三种。在目标2中，我们将确定DM的性能参数，并演示使用正常和乳腺癌患者的FFPE技术。这将包括DM与RT-PCR的比较。用DM检测miR靶点将是革命性的，并从根本上改变我们使用和监测癌症生物标志物的方式。这种基于量子技术的发展将把诊断测试时间从几天缩短到几分钟，并使实时护理成为可能，从而节省资金、时间和生命。